Discovering a positive Antinuclear Antibody (ANA) test can be concerning, but it presents an invitation for further clinical evaluation rather than a definitive diagnosis. While a positive ANA can certainly be the first step in diagnosing a systemic rheumatic disorder such as Systemic Lupus Erythematosus (lupus), Sjögren's disease, Myositis or Scleroderma, it is not exclusive to rheumatology. It may also point to organ-specific autoimmune conditions affecting the thyroid, neurological, or hepatic (liver) systems, which may warrant collaboration with other specialists. Additionally, a positive result can transiently arise during active infections or in association with certain oncological conditions. Because this test is highly sensitive, it frequently captures benign immune nuances or yields false positives, emphasizing the need for expert clinical correlation.  ​ [Read our full guide on de-mystifying a positive ANA test]

Inflammatory arthritis, especially autoimmune inflammatory arthritis, encompasses a group of immune-mediated conditions, such as Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Reactive Arthritis, Enteropathic (Inflammatory Bowel Disease-associated) Arthropathies. While these conditions predominately affect joints, they are systemic in nature, and can affect organs beyond the musculoskeletal system, resulting in interstitial lung disease, rheumatoid vasculitis, inflammatory eye disease (such as scleritis, conjunctivitis, uveitis), a variety of skin conditions (such as rheumatoid nodules, psoriasis, erythema nodosum, pyoderma gangrenosum), ​or aortic valve incompetence. Conversely, major systemic autoimmune rheumatic disorders, such as Systemic Lupus Erythematosus (lupus), Sjogren's disease, Myositis, Scleroderma, Systemic Vasculitis, frequently present with joints involvement that can mimic joint-predominant conditions. Given the overlapping and complex nature of these conditions, the optimal approach requires a comprehensive diagnostic evaluation. This allows for a tailored treatment strategy that accounts for existing or potential comorbidities, paired with vigilant surveillance to achieve joints protection and preserve overall health.

Crystal arthropathies, commonly Gout and Pseudogout (Calcium Pyrophosphate Deposition Disease, or CPPD), are distinct forms of inflammatory arthritis. Unlike autoimmune conditions where the immune system attacks our body, the inflammation here is triggered by the physical deposition of crystals, specifically, uric acid crystals in Gout, and calcium pyrophosphate crystals in Pseudogout. While these crystals can occasionally accumulate in other areas, such as the kidneys (forming kidney stones), or soft tissues (forming nodules known as tophi), they fortunately do not prompt the multi-organ immune attacks characteristic of autoimmune disorders.    ​While gout is strongly influenced by a combination of genetics and lifestyle factors, Pseudogout may be secondary to an underlying condition, such as parathyroid disorder, hemochromatosis, hypophosphatamia or other metabolic or mineral imbalance, or entirely idiopathic (without an apparent cause). Because of these distinct underlying drivers, each condition requires a uniquely tailored management strategy to control the disease and prevent future flares.

Systemic autoimmune rheumatic disorders occur when our immune system inadvertently attack the healthy tissues throughout the body. This broad spectrum of complex conditions includes Systemic Lupus Erythematosus (lupus), Sjögren's Disease, Scleroderma (Systemic Sclerosis), , Mixed Connective Tissue Disease, Overlap Syndrome, Polymyalgia Rheumatica, Inflammatory Myopathies (including a few distinct subtypes that share different clinical, laboratory, pathological presentations). It also includes the Vasculitides, a highly complex group of disorders that comprises Giant Cell Arteritis, Takayasu Arteritis, Polyarteritis Nodosa, ANCA-associated Vasculitis, Cryoglobulinemic Vasculitis and Relapsing Polychondritis, among others. ​These conditions are inherently intricate, with ongoing research continually revealing their perplexing molecular disease pathways and driving an ever-changing landscape of therapeutic options.

To understand autoinflammatory conditions and how they differ from autoimmune conditions, it helps to look at the basic structure of our immune system. Broadly speaking, our immune system serves as our internal guardian and operates in two sectors with close collaboration: the innate immune system is the defense network we are born with and it remains relatively constant throughout our lives, this includes physical barriers like the skin, specialized white blood cells that immediately destroy foreign invaders. The adaptive immune system, by contrast, is highly specialized and relentlessly evolves over a lifetime; it learns to target specific threats, responds to vaccinations, and if it goes wrong, can cause autoimmune conditions. An autoinflammatory disorder occurs when the primary malfunction resides within the innate immune system. Because this primitive system acts as a broad, immediate responder, its malfunction can produce unprovoked, nonspecific, widespread inflammatory processes. Examples of these disorders include Familial Mediterranean Fever (FMF), Adult-Onset Still's Disease (AOSD), and Behçet's Disease. Autoinflammatory conditions can be exceptionally rare and highly complex. Because their symptoms frequently mimic common infections or other medical issues, the average time to reach an accurate diagnosis can span several years. This underscores the critical need for an expert, comprehensive evaluation; in certain cases, a referral to a tertiary academic center with specialized experience in these exceptionally rare conditions may be necessary.

Rheumatologists are equipped to offer advanced therapies for Osteoporosis, such as Denosumab (Prolia), Teriparatide (Forteo), Abaloparatide (Tymlos) and Romosozumab (Evenity), in addition to Bisphosphonates like Alendronate (Fosamax) and Zoledronic Acid (Reclast). In our practice, we treat post-menopausal women who have developed osteoporosis, while actively screening our other rheumatology patients who present with major risk factors, most notably, long-term steroid use. Because managing rheumatic disorder historically and currently requires steroids, our field holds unique expertise in managing Glucocorticoid-Induced Osteoporosis (GIOP), a condition for which American College of Rheumatology (ACR) has published dedicated clinical guidelines (such as the 2017, and 2022 ACR GIOP updates). When evaluating bone loss, we perform a comprehensive secondary workup to identify whether there is an underlying trigger, which may warrant a different management approach. Simultaneously, we focus on lifestyle and dietary consultation in conjunction with advanced pharmaceutical therapy when indicated.

Osteoarthritis is the most common type of arthritis, known as degenerative joint disease or "wear-and-tear" arthritis. Clinical approaches to Osteoarthritis vary across the field. In our practice, the focus is on a thorough evaluation to reach an accurate diagnosis; this includes ruling out an underlying rheumatic condition that could affect the joints, such as the above-mentioned inflammatory arthritis or a systemic autoimmune condition, which can co-exist with osteoarthritis. If Osteoarthritis is confirmed and a rheumatic condition is ruled out, we provide comprehensive consultations to guide lifestyle modifications, provide physical therapy referrals and orthopedic specialist or pain management referrals if indicated.

The diagnosis and management of Fibromyalgia can be challenging for both the providers and the patients. Because it presents with a wide range of symptoms, such as widespread pain, fatigue, stiffness, sleep disturbances, cognitive problems ("fibrofog") and mood disorders, furthermore, it commonly coexists with tension or migraine headaches, irritable bowel syndrome, interstitial cystitis, chronic pelvic pain, and hypersensitivity. Scientific research indicates that Fibromyalgia is primarily a central pain processing disorder, rather than an immune-mediated condition. However, because Fibromyalgia and autoimmune rheumatic disorders share overlapping symptoms, and individuals with underlying autoimmune rheumatic diseases have a higher prevalence of developing co-existing Fibromyalgia, distinguishing between the two requires meticulous, expert evaluation. ​In our practice, the primary focus is to provide a comprehensive consultation to ensure diagnostic clarity. Our goal is to partner with our patients to carefully rule out concurrent rheumatic disorders, establish an accurate diagnosis, and form a personalized roadmap for lifestyle and symptom management. It is also vital to investigate the root causes of associated symptoms like headaches, gastrointestinal symptoms and sleep disorders to ensure an organic etiology is ruled out. Fibromyalgia is best managed through a multidisciplinary approach tailored to the individual's predominant symptoms. Patients may not require long-term rheumatology follow-ups. This initial time together is designed to empower our patients with the answers, validation, and personalized guidance needed to confidently navigate their health journey moving forward and improve their quality of life.